Contact Us
EN | 简 | 繁 |
Cervical Cancers & Genital Warts
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
REC603
More+
Type of Vaccine:

Recombinant HPV 9-valent vaccine

Adjuvant Systems:
Alum
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
REC601
More+
Type of Vaccine:

Recombinant HPV bivalent vaccine(Types 16/18)

Adjuvant Systems:
Alum
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
REC602
More+
Type of Vaccine:

Recombinant HPV bivalent vaccine(Types 6/11)

Adjuvant Systems:
Alum
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
REC604a
More+
Type of Vaccine:

2nd-generation recombinant HPV quadrivalent vaccine

Adjuvant Systems:
BFA04
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
REC604b
More+
Type of Vaccine:

2nd-generation recombinant HPV 9-valent vaccine

Adjuvant Systems:
Undisclosed novel adjuvant
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Covid-19
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
ReCOV
More+
Type of Vaccine:

Recombinant COVID-19 vaccine

Adjuvant Systems:
BFA03
Product Rights:
Co-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
R520A
More+
Type of Vaccine:

mRNA COVID-19 Vaccine

Adjuvant Systems:
-
Product Rights:
Co-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Shingles
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
REC610
More+
Type of Vaccine:

Recombinant shingles vaccine

Adjuvant Systems:
BFA01
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Adult TB
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
REC607
More+
Type of Vaccine:

Sendai virus vector vaccine

Adjuvant Systems:
-
Product Rights:
License-in
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Candidates:
REC606
More+
Type of Vaccine:

Recombinant adult TB vaccine

Adjuvant Systems:
BFA01
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
Flu
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
REC617
More+
Type of Vaccine:

Recombinant influenza quadrivalent vaccine

Adjuvant Systems:
BFA03
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone:
HFMD
iconArrow
Candidates
Type of Vaccine
Adjuvant Systems
Product Rights
Commercial Rights
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commer...
Future Milestone
Candidates:
REC605
More+
Type of Vaccine:

Recombinant HFMD quadrivalent vaccine

Adjuvant Systems:
Alum
Product Rights:
Self-developed
Commercial Rights:
Global
R&D Status
Pre-clinical
IND
Phase I
Phase II
Phase III
Commercialization
Future Milestone: